Beijing Centergate Technologies (holding) Co (000931) Fair Value & Analysis
Healthcare · CN · Market cap 3.1B CNY
Fair value as of: Jul 25, 2026
From 7 valuation models · updated 16 days ago
Share price −0.7% over the past month.
Below-average quality, and screening another 40% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥3.46). The favourable scenario is already priced in.
- Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (¥1.62 to ¥3.46) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 25, 2026.
How to read this chart
60‑month range ¥3.33 – ¥8.80 · fair‑value band ¥1.62 – ¥3.46 · the ¥4.22 price screens above the ¥2.54 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 25, 2026.
Analysis
Beijing Centergate Technologies (holding) Co (000931) currently trades at ¥4.22, while our model-based Fair Value estimate is ¥2.54, implying the stock looks roughly 39.8% overvalued today. The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Beijing Centergate Technologies (holding) Co generated revenue of 2.3B CNY at a net margin of 0.7%. Revenue declined 23.4% year over year. It earns a return on equity of 1.5%. Net debt stands at 386M CNY. Fundamentals as of Jul 25, 2026
Our scenario range runs from ¥1.62 (bear case) to ¥3.46 (bull case); at ¥4.22, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 28% below its 52-week high and 8% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -40%, 000931 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 7 models by family
Widest divergence: Multiples (¥3.19) versus Asset-Based (¥1.45). Highest evidence: Residual Income (76).
Notify me when 000931 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 25, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 45 · Market factors (momentum, volatility) 36
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Beijing Centergate Technologies (holding) Co., Ltd. engages in the pharmaceutical industry in China and internationally.
Full company description
Beijing Centergate Technologies (holding) Co., Ltd. engages in the pharmaceutical industry in China and internationally. The company offers Anemarrhena saponin BII and capsules for vascular dementia treatment; Bifonazole API, an opioid receptor antagonist; Naloxone Hydrochloride injection to relieve acute ethanol poisoning; Naltrexone Hydrochloride tablets to block the pharmacological effects of exogenous opioids; Hydrocodone acetaminophen tablets for the treatment of moderate to severe pain; Ambroxol Hydrochloride injection for acute and chronic lung diseases; Tramadol Hydrochloride injection for moderate to severe pain; Febuxostat tablets for long-term treatment of hyperuricemia; and Glipizide Dispersible tablets to improve glycemic control in adults with type 2 diabetes. It also provides Metoprolol succinate API for hypertension and coronary heart disease; Bisoprolol Fumarate tablets for chronic stable heart failure; Tropisetron Mesylate injection for prevention and treatment of nausea and vomiting; Cediodine lozenges used for chronic pharyngitis; Phencynonate Hydrochloride tablets used to prevent motion sickness; Oxycodone Hydrochloride injection, an analgesic; Bifonazole cream used to treat various fungal skin diseases; Huperzine A to improve memory impairment; Wujia Biochemical capsule for vaginal bleeding caused by qi deficiency and blood stasis; Lactobacillus tablets used for abnormal intestinal fermentation; Tramadol Hydrochloride tablets for the treatment of pain in adults; Aminophene Tramadol tablets for treatment of moderate to severe acute pain; Clindamycin phosphate vaginal gel used to treat bacterial vaginosis; and Benidipine Hydrochloride tablets for essential hypertension and angina pectoris. Beijing Centergate Technologies (holding) Co., Ltd. was founded in 1999 and is based in Beijing, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Beijing Centergate Technologies (holding) Co reported revenue of ¥2.4B in FY2025 versus ¥2.0B in FY2021, a compound +5.7%/yr. Reported net income was ¥47.9M in FY2025.
of which total revenue +1.8 pp · buybacks/dilution −1.2 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
000931 screens 40% overvalued. Compare with Intuitive Surgical, Inc →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare Beijing Centergate Technologies (holding) Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Beijing Centergate Technologies (holding) Co (000931) overvalued or undervalued?
What is the fair value of 000931?
What is the quality score of 000931?
What is the revenue of Beijing Centergate Technologies (holding) Co (000931)?
What is the net profit margin of 000931?
Does Beijing Centergate Technologies (holding) Co pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Beijing Centergate Technologies (holding) Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.